Sinotau Pharmaceutical Group is conducting a Phase 3 clinical trial to evaluate the efficacy and safety of XTR006, a PET radiopharmaceutical, for detecting brain neurofibrillary tangles (NFTs) in elderly subjects. The trial targets a significant market segment, including individuals with Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD), conditions that are increasingly prevalent in aging populations. The successful validation of XTR006 could position Sinotau favorably in the neuroimaging market, which is becoming increasingly competitive with advancements in diagnostic technologies. The trial's outcomes may enhance the company's portfolio and provide a potential first-mover advantage in the specific niche of NFT detection, which is critical for early diagnosis and treatment of neurodegenerative diseases.